Bristol Debt Ratio from 2010 to 2024

BMY Stock

USD 58.78 0.09 0.15%

Bristol Myers Debt Ratio yearly trend continues to be fairly stable with very little volatility. Debt Ratio is likely to outpace its year average in 2024. During the period from 2010 to 2024, Bristol Myers Debt Ratio regression line of annual values had r-squared of 0.55 and arithmetic mean of 0.31. View All Fundamentals

Debt Ratio

First Reported

2010-12-31

Previous Quarter

0.41795311

Current Value

0.44

Quarterly Volatility

0.15318485

Credit Downgrade

Yuan Drop

Covid

Check Bristol Myers financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bristol Myers' main balance sheet or income statement drivers, such as Depreciation And Amortization of 10.3 B, Interest Expense of 1.2 B or Selling General Administrative of 3.6 B, as well as many indicators such as Price To Sales Ratio of 2.98, Dividend Yield of 0.0374 or PTB Ratio of 6.92. Bristol financial statements analysis is a perfect complement when working with Bristol Myers Valuation or Volatility modules.

Check out the analysis of Bristol Myers Correlation against competitors.

Latest Bristol Myers' Debt Ratio Growth Pattern

Below is the plot of the Debt Ratio of Bristol Myers Squibb over the last few years. It is Bristol Myers' Debt Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bristol Myers' overall financial position and show how it may be relating to other accounts over time.

Debt Ratio

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Debt Ratio

Timeline

Bristol Debt Ratio Regression Statistics

	Arithmetic Mean	0.31
	Geometric Mean	0.28
	Coefficient Of Variation	48.80
	Mean Deviation	0.13
	Median	0.24
	Standard Deviation	0.15
	Sample Variance	0.02
	Range	0.5971
	R-Value	0.74
	Mean Square Error	0.01
	R-Squared	0.55
	Significance	0
	Slope	0.03
	Total Sum of Squares	0.33

Bristol Debt Ratio History

	2024	0.44
	2023	0.42
	2021	0.41
	2020	0.43
	2019	0.36
	2018	0.69
	2017	0.24

Other Fundumenentals of Bristol Myers Squibb

Cash Flow To Debt Ratio

Bristol Myers Debt Ratio component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Good Will	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Short Term Investments	Capital Stock	Common Stock	Long Term Debt	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Total Permanent Equity	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital
Total Assets		0.89	0.98	-0.07	0.76	0.97	0.99	0.94	0.85	0.96	0.6	0.12	0.88	0.88	0.98	-0.76	0.83	0.61	-0.97	0.37	0.97	0.93	0.79	-0.5	-0.35	0.91	0.98	0.86
Total Stockholder Equity	0.89		0.84	0.13	0.5	0.82	0.85	0.76	0.73	0.93	0.62	0.36	0.81	0.81	0.85	-0.51	0.73	0.33	-0.87	0.28	0.81	0.73	0.82	-0.51	-0.31	0.83	0.89	0.79
Net Debt	0.98	0.84		-0.17	0.82	0.98	0.99	0.93	0.89	0.94	0.56	-0.02	0.91	0.91	0.99	-0.82	0.87	0.66	-0.99	0.44	0.99	0.97	0.76	-0.54	-0.37	0.93	0.98	0.85
Retained Earnings	-0.07	0.13	-0.17		-0.11	-0.03	-0.11	-0.05	-0.16	-0.13	0.44	0.49	-0.15	-0.15	-0.17	0.05	-0.07	-0.44	0.19	-0.45	-0.23	-0.26	-0.07	0.43	-0.13	-0.21	-0.19	-0.16
Net Receivables	0.76	0.5	0.82	-0.11		0.88	0.8	0.86	0.87	0.62	0.53	-0.15	0.81	0.81	0.8	-0.98	0.84	0.69	-0.75	0.54	0.82	0.9	0.33	-0.35	-0.51	0.73	0.75	0.63
Good Will	0.97	0.82	0.98	-0.03	0.88		0.98	0.95	0.9	0.9	0.63	0.03	0.9	0.9	0.97	-0.88	0.88	0.65	-0.95	0.41	0.97	0.97	0.7	-0.47	-0.42	0.9	0.95	0.82
Total Liab	0.99	0.85	0.99	-0.11	0.8	0.98		0.96	0.87	0.94	0.61	0.05	0.9	0.9	0.99	-0.81	0.85	0.64	-0.98	0.4	0.98	0.95	0.77	-0.51	-0.37	0.93	0.97	0.86
Total Current Assets	0.94	0.76	0.93	-0.05	0.86	0.95	0.96		0.85	0.84	0.68	0.07	0.86	0.86	0.94	-0.86	0.81	0.67	-0.89	0.37	0.94	0.94	0.61	-0.4	-0.36	0.87	0.9	0.82
Short Term Debt	0.85	0.73	0.89	-0.16	0.87	0.9	0.87	0.85		0.82	0.53	0.05	0.84	0.84	0.87	-0.83	0.85	0.56	-0.87	0.57	0.87	0.9	0.6	-0.48	-0.43	0.87	0.88	0.75
Intangible Assets	0.96	0.93	0.94	-0.13	0.62	0.9	0.94	0.84	0.82		0.5	0.17	0.83	0.83	0.95	-0.62	0.78	0.52	-0.97	0.39	0.93	0.87	0.88	-0.63	-0.32	0.93	0.98	0.87
Accounts Payable	0.6	0.62	0.56	0.44	0.53	0.63	0.61	0.68	0.53	0.5		0.19	0.64	0.64	0.56	-0.61	0.6	0.09	-0.54	-0.13	0.52	0.51	0.39	-0.01	-0.13	0.5	0.51	0.4
Short Term Investments	0.12	0.36	-0.02	0.49	-0.15	0.03	0.05	0.07	0.05	0.17	0.19		-0.04	-0.04	0.04	0.21	-0.1	-0.23	-0.02	-0.17	-0.02	-0.09	0.24	0.09	-0.05	0.16	0.1	0.3
Capital Stock	0.88	0.81	0.91	-0.15	0.81	0.9	0.9	0.86	0.84	0.83	0.64	-0.04		1.0	0.9	-0.83	0.95	0.67	-0.9	0.46	0.91	0.92	0.64	-0.52	-0.35	0.86	0.9	0.78
Common Stock	0.88	0.81	0.91	-0.15	0.81	0.9	0.9	0.86	0.84	0.83	0.64	-0.04	1.0		0.9	-0.83	0.95	0.67	-0.9	0.46	0.91	0.92	0.64	-0.52	-0.35	0.86	0.9	0.78
Long Term Debt	0.98	0.85	0.99	-0.17	0.8	0.97	0.99	0.94	0.87	0.95	0.56	0.04	0.9	0.9		-0.8	0.85	0.66	-0.99	0.45	1.0	0.96	0.76	-0.58	-0.4	0.96	0.99	0.89
Treasury Stock	-0.76	-0.51	-0.82	0.05	-0.98	-0.88	-0.81	-0.86	-0.83	-0.62	-0.61	0.21	-0.83	-0.83	-0.8		-0.87	-0.7	0.76	-0.41	-0.81	-0.9	-0.37	0.31	0.4	-0.7	-0.74	-0.59
Property Plant Equipment	0.83	0.73	0.87	-0.07	0.84	0.88	0.85	0.81	0.85	0.78	0.6	-0.1	0.95	0.95	0.85	-0.87		0.67	-0.86	0.54	0.86	0.89	0.64	-0.55	-0.47	0.8	0.84	0.72
Current Deferred Revenue	0.61	0.33	0.66	-0.44	0.69	0.65	0.64	0.67	0.56	0.52	0.09	-0.23	0.67	0.67	0.66	-0.7	0.67		-0.62	0.5	0.73	0.78	0.39	-0.45	-0.2	0.6	0.65	0.68
Net Tangible Assets	-0.97	-0.87	-0.99	0.19	-0.75	-0.95	-0.98	-0.89	-0.87	-0.97	-0.54	-0.02	-0.9	-0.9	-0.99	0.76	-0.86	-0.62		-0.44	-0.98	-0.94	-0.83	0.6	0.35	-0.95	-0.99	-0.86
Total Permanent Equity	0.37	0.28	0.44	-0.45	0.54	0.41	0.4	0.37	0.57	0.39	-0.13	-0.17	0.46	0.46	0.45	-0.41	0.54	0.5	-0.44		0.49	0.52	0.17	-0.75	-0.76	0.51	0.48	0.45
Long Term Debt Total	0.97	0.81	0.99	-0.23	0.82	0.97	0.98	0.94	0.87	0.93	0.52	-0.02	0.91	0.91	1.0	-0.81	0.86	0.73	-0.98	0.49		0.98	0.74	-0.6	-0.39	0.95	0.98	0.89
Capital Surpluse	0.93	0.73	0.97	-0.26	0.9	0.97	0.95	0.94	0.9	0.87	0.51	-0.09	0.92	0.92	0.96	-0.9	0.89	0.78	-0.94	0.52	0.98		0.65	-0.56	-0.37	0.9	0.95	0.82
Deferred Long Term Liab	0.79	0.82	0.76	-0.07	0.33	0.7	0.77	0.61	0.6	0.88	0.39	0.24	0.64	0.64	0.76	-0.37	0.64	0.39	-0.83	0.17	0.74	0.65		-0.51	-0.11	0.76	0.8	0.78
Long Term Investments	-0.5	-0.51	-0.54	0.43	-0.35	-0.47	-0.51	-0.4	-0.48	-0.63	-0.01	0.09	-0.52	-0.52	-0.58	0.31	-0.55	-0.45	0.6	-0.75	-0.6	-0.56	-0.51		0.55	-0.65	-0.63	-0.6
Short Long Term Debt	-0.35	-0.31	-0.37	-0.13	-0.51	-0.42	-0.37	-0.36	-0.43	-0.32	-0.13	-0.05	-0.35	-0.35	-0.4	0.4	-0.47	-0.2	0.35	-0.76	-0.39	-0.37	-0.11	0.55		-0.46	-0.38	-0.39
Cash And Equivalents	0.91	0.83	0.93	-0.21	0.73	0.9	0.93	0.87	0.87	0.93	0.5	0.16	0.86	0.86	0.96	-0.7	0.8	0.6	-0.95	0.51	0.95	0.9	0.76	-0.65	-0.46		0.96	0.94
Net Invested Capital	0.98	0.89	0.98	-0.19	0.75	0.95	0.97	0.9	0.88	0.98	0.51	0.1	0.9	0.9	0.99	-0.74	0.84	0.65	-0.99	0.48	0.98	0.95	0.8	-0.63	-0.38	0.96		0.89
Net Working Capital	0.86	0.79	0.85	-0.16	0.63	0.82	0.86	0.82	0.75	0.87	0.4	0.3	0.78	0.78	0.89	-0.59	0.72	0.68	-0.86	0.45	0.89	0.82	0.78	-0.6	-0.39	0.94	0.89

Click cells to compare fundamentals

About Bristol Myers Financial Statements

Bristol Myers investors use historical fundamental indicators, such as Bristol Myers' Debt Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Bristol Myers. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Debt Ratio	0.42	0.44
Cash Flow To Debt Ratio	0.35	0.33

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Bristol Stock Analysis

When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bristol Debt Ratio from 2010 to 2024

Latest Bristol Myers' Debt Ratio Growth Pattern

Bristol Debt Ratio Regression Statistics

Bristol Debt Ratio History

Other Fundumenentals of Bristol Myers Squibb

Bristol Myers Debt Ratio component correlations

About Bristol Myers Financial Statements

Also Currently Popular

Additional Tools for Bristol Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY